TXP1

Pipeline

The original chart is reproduced unchanged, followed by an accessible table that describes it.

Original pipeline figure

Original Ossianix pipeline chart: five TXP1 programmes with arrows across In vitro, In vivo mice and In vivo NHP columns; TXP1-TrkB and TXP1-CD20 arrows reach the IND boundary with funded labels from MJFF and the National MS Society; no arrow enters Phase I. — Source: ossianix.co.uk Science & Technology. Arrow endpoints and funding logos do not prove IND submission or clearance, trial initiation or efficacy.

Chart, described

Programme	Indication	Position in the chart	Funding (announced)
TXP1-TrkB^mAb	Parkinson’s disease	Through in vivo NHP, towards the IND boundaryPhase I: not reached	Michael J. Fox Foundation, US$1.26m — announced 9 Jan 2025 (MJFF funding year 2024). Preclinical.
TXP1-CD20^mAb	Multiple sclerosis	Through in vivo NHP, towards the IND boundaryPhase I: not reached	National MS Society Fast Forward, US$0.8m — announced 7 Jul 2026. Preclinical PK/PD and safety work.
TXP1-Her2^mAb	Neuro-oncology	Within in vivo NHPPhase I: not reached	—
TXP1-oligo1	Undisclosed	Near the start of in vivo NHPPhase I: not reached	—
TXP1-oligo2	Undisclosed	Within in vivo micePhase I: not reached	—

ClinicalTrials.gov API v2 searched on 17 October 2026 for “Ossianix” and “TXP1”: no studies returned. A limited search, not proof of absence of all human studies.

Historical: Attralus AT-04 + TXP1 option and licence agreement announced 17 November 2022. Its current exercise or clinical status is not established.